Eisai Inc. Collaborates with C2N to Build Awareness and Real-World Evidence for Blood-based Assays

0
41
Eisai Inc. Collaborates with C2N to Build Awareness and Real-World Evidence for Blood-based Assays

TOKYO, Aug 24, 2022 – (JCN Newswire) – Eisai Co., Ltd. announced today that its U.S. subsidiary Eisai Inc. has entered into a memorandum of understanding with C2N Diagnostics (“C2N”) that will seek to build awareness about how blood-based assays in the diagnosis for people living with cognitive impairment…
Read More